MDxHealth is a molecular diagnostics company that develops and commercializes epigenetic tests for cancer assessment and personalized patient treatment. Its first commercial product, the ConfirmMDx™ for Prostate Cancer test, is designed to help distinguish patients who have a true negative biopsy from those who may have occult cancer. MDxHealth addresses a significant and growing unmet medical need: better cancer diagnosis and improved treatment information. The company has an exclusive platform and a strong pipeline of epigenetic products focused on developing products for brain and lung cancers.